The study follows a short treatment period after semaglutide is given. During this time, the study team checks how well the medicine is tolerated and records common stomach and body symptoms such as nausea, vomiting, constipation, diarrhoea, abdominal pain, dizziness, fatigue, headache, appetite changes, and changes in body weight. The main focus is on how strong nausea is during the first few days after treatment.

The trial is randomised, which means the study treatment is assigned by chance, and double-blind, which means neither the participants nor the study team know who receives which treatment during the study. The trial is also placebo-controlled, so one group receives placebo instead of the active added medicine.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

People in the study receive one of several weekly dose levels of NNC0487-0111 or placebo. The treatment is given with a pre-filled pen and the study lasts for many months. During the study, body weight, blood sugar control, and other health changes are followed, along with any unwanted effects.

The study is designed to find out whether NNC0487-0111 can help reduce body weight in people who have excess body weight and type 2 diabetes. It also looks at changes in waist size, blood sugar, blood pressure, blood fats, and quality of life, as well as safety issues such as low blood sugar and other side effects.

The treatment will involve receiving regular injections of the study medications for up to 52 weeks. Mirikizumab is a type of medication called a monoclonal antibody, which works by targeting specific parts of the immune system. Tirzepatide is a medication that can help with weight management. Some participants will receive both active medications, while others will receive Mirikizumab with placebo.

The study will measure how many participants achieve two goals at the same time: improvement in their Ulcerative Colitis symptoms and a significant reduction in their body weight. The medications will be given through injections either under the skin or into a vein, depending on the specific medication being administered.

Participants in the study will receive either maridebart cafraglutide or a placebo over a period of 72 weeks. Throughout the study, changes in body weight, waist circumference, and other health markers such as blood pressure and blood sugar levels will be monitored. The study will also assess the impact of weight changes on the quality of life of the participants.

The study aims to provide valuable information on the effectiveness and safety of maridebart cafraglutide for managing weight in individuals with Type 2 Diabetes Mellitus. This research could potentially lead to new treatment options for those struggling with weight management in the context of diabetes.

The purpose of this study is to find out if CagriSema can improve markers that show how chronic kidney disease is progressing in people with type 2 diabetes who are living with overweight or obesity. Participants may also be taking other medicines during the study, such as enalapril maleate, dapagliflozin propanediol, or finerenone, which are used to help protect the kidneys and manage related conditions. The study will measure changes in urine protein levels, kidney function, body weight, waist size, blood sugar control, and blood pressure. It will also track any side effects or health problems that occur during treatment.

During the study, participants will receive their assigned treatment for up to 35 weeks. They will attend regular visits where measurements will be taken and blood and urine samples will be collected to check how well the treatment is working and to monitor safety. The study team will look at changes from the start of the study to the end of treatment to understand the effects of each treatment option.

During the study, participants will receive either cagrilintide at different dose levels or placebo for a treatment period of up to 64 weeks. All participants will also receive guidance on lifestyle changes to support weight management. The study will measure changes in body weight and track how many people achieve weight loss of at least 5%, 10%, or 15% of their starting weight. Other measurements will include changes in waist size, blood sugar control measured by HbA1c (a test that shows average blood sugar levels over time), blood pressure, and various blood fats such as cholesterol and triglycerides.

The study will also assess quality of life using questionnaires that ask about physical function and overall well-being, and will monitor any side effects or health problems that occur during treatment. Safety will be carefully tracked, including any episodes of low blood sugar, which can happen when blood sugar drops below normal levels. Participants may continue taking their usual diabetes medications during the study if they have been on a stable dose for a certain period before joining.

The purpose of the study is to evaluate how different forms and doses of semaglutide affect the way blood clots in these specific groups. One group of participants will use Rybelsus, which is an oral tablet, while another group may use Wegovy, which is a subcutaneous injection, meaning it is administered through a needle just under the skin. Some participants will receive a placebo or compare these treatments against existing medications like acetylsalicylic acid.

During the study, participants will follow a specific treatment plan involving either tablets or injections over a set period. Researchers will monitor various biological markers, including indicators of inflammation and how well the blood vessels are functioning, to observe changes in the body’s response to the medications.

During the study, participants will receive either Eloralintide or a placebo through subcutaneous use, which means the medication is injected into the fatty tissue just under the skin. The medication is provided in a pre-filled syringe for once-weekly administration. This is a randomized and double-blind study, meaning that neither the participants nor the researchers know beforehand which treatment is being administered. This method is used to ensure the results are as objective as possible.

The purpose of the study is to determine if Eloralintide is more effective than a placebo at helping to change body weight. During the study, participants will be assigned to receive either the active medication or a placebo once every week. The process is double-blind, meaning that neither the participants nor the researchers know who is receiving the actual drug or the inactive substance until the study is complete. Participants will be monitored over a period of time to observe changes in weight and to ensure safety.

Participants in the study will receive either the test medication or a placebo. The medication is administered through a subcutaneous injection, which means it is delivered into the fatty layer of tissue just under the skin, using a pre-filled pen once per week. During the study, changes in body weight, waist size, and various health measurements will be monitored. Additionally, the impact on knee pain, stiffness, and physical movement will be observed to see how the treatment affects daily function.

Participants will receive the treatment through a subcutaneous injection, which means the medicine is administered into the fatty layer of tissue just under the skin, using a pre-filled pen once a week. Throughout the study, changes in body weight and levels of pain in the knee will be observed. Other factors such as physical function, waist size, and certain blood measurements like cholesterol and blood pressure may also be monitored to understand the overall impact of the treatment.

Participants in the study will receive either Eloralintide or a placebo through a subcutaneous injection, which is a method of delivering medication into the fatty tissue just under the skin. The medication is administered once every week using a pre-filled syringe containing a solution for injection. During the course of the study, the changes in body weight and knee pain levels will be monitored over a period of time.

Participants in the study will receive either the study drug or a placebo through a subcutaneous injection, which means the medicine is delivered by a needle into the fatty layer of tissue just under the skin. The medication is provided as a solution for injection in a pre-filled syringe and is intended to be used once every week. This research is designed to determine if Eloralintide can lead to a greater reduction in body weight compared to the placebo over a period of time.

The medication, Eloralintide, is administered as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin, using a pre-filled syringe once per week. During the study, the effects of this treatment on body weight and the apnea-hypopnea index—a measurement used to track how many times breathing becomes shallow or stops during sleep—will be monitored over time.

Participants in the study will receive weekly injections of either Tirzepatide or a placebo over a period of 17 weeks. Throughout the study, researchers will monitor changes in the participants’ body mass index (BMI), which is a measure of body fat based on height and weight. The study aims to see if Tirzepatide can help reduce BMI and improve other health conditions related to being overweight or having obesity.

The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving Tirzepatide and who is receiving the placebo. This helps ensure that the results are unbiased. The study is expected to continue until early 2026, with the recruitment of participants starting in late 2023. The findings from this trial could provide valuable insights into the potential benefits of Tirzepatide for adolescents struggling with weight management and related health issues.

The purpose of this study is to compare different doses of AMG 133 to placebo to see how well they work in helping people lose weight and keep it off over a period of time. The study will look at two groups of people: those who have weight problems without diabetes and those who have weight problems with type 2 diabetes. The study will measure how much weight people lose and whether they can maintain that weight loss.

During the study, participants will receive treatment for up to 104 weeks, which is about two years. The study will track changes in body weight, blood sugar levels measured by a test called hemoglobin A1c or HbA1c, waist size, blood pressure, and various substances in the blood such as cholesterol and triglycerides. Some participants will also have body composition measured using a scanning method called dual-energy X-ray absorptiometry or DXA, which shows how much fat and muscle the body has. The study will also monitor how the medication moves through the body and check for any side effects to determine if the treatment is safe and well-tolerated.

Tirzepatide is given as an injection under the skin using a pre-filled pen once a week. The study will compare people taking tirzepatide to people taking placebo to see if there is a difference in major health events. These events include death from any cause, heart attack that is not fatal, stroke that is not fatal, procedures to restore blood flow to the heart, or problems related to heart failure. The study is looking at whether tirzepatide can help prevent these serious health problems in people who are overweight or have obesity and also have heart disease or risk factors for heart disease such as smoking, abnormal levels of fats in the blood, high blood pressure, or kidney disease.

People in the study will continue taking the treatment for a period of time while doctors monitor their health and track whether any of these major health events occur. The study will measure how long it takes until the first occurrence of any of these serious health problems happens in people taking tirzepatide compared to those taking placebo. The treatment period can last up to 324 weeks.

The purpose of this study is to find out how well CagriSema works in helping people lose weight compared to placebo, when used together with diet and exercise changes. The study will also look at whether people can achieve certain weight loss goals, such as losing at least five percent or twenty percent of their body weight. Additionally, the study will examine how the treatment affects waist size, blood sugar control measured by a test called HbA1c, blood pressure, and quality of life related to physical function. The safety of the treatment will be carefully monitored by tracking any unwanted effects that occur during the study, including episodes of low blood sugar.

During the study, participants will receive their assigned treatment for up to one year. Throughout this time, they will have regular visits where doctors will check their weight, blood sugar levels, blood pressure, and overall health. The study will collect information about how the treatment affects the body and whether it causes any side effects. This research aims to provide information about whether this combination treatment could be a helpful option for people with type 2 diabetes who are also struggling with excess weight.

The purpose of this research is to determine if cagrilintide is more effective than placebo in helping people lose weight. The study will specifically look at whether the medication can help people achieve a reduction of at least 5% of their body weight. During the study, participants will receive either cagrilintide or placebo injections for approximately 64 weeks.

The study will measure various health indicators including changes in body weight, waist size, blood pressure, and different types of cholesterol in the blood. It will also assess how the treatment affects quality of life and overall health. Throughout the study, participants’ safety will be monitored by tracking any side effects that may occur.

The purpose of this research is to evaluate how well orforglipron tablets taken once daily work compared to placebo in reducing body weight in people without diabetes and improving blood sugar control in those with diabetes. The study consists of two parts: one for participants with obesity or overweight who have at least one weight-related health condition but do not have diabetes, and another for those who have both weight issues and Type 2 Diabetes.

Participants will first go through a screening period of about 4 weeks before being enrolled in the appropriate study group based on whether they have diabetes. The treatment period will last 40 weeks, during which participants will take either orforglipron or placebo. For diabetes patients, hemoglobin A1c (a measure of average blood sugar levels over 2-3 months) will be monitored to assess improvements in blood sugar control.

The purpose of this study is to determine if tirzepatide is more effective than placebo in improving ovarian function in women with PCOS who have overweight or obesity. Tirzepatide is a medication that helps regulate blood sugar and can promote weight loss. The study will focus specifically on whether the medication can help normalize menstrual cycles in women with PCOS.

Participants will receive either tirzepatide or placebo through self-injection for 72 weeks (approximately 1.5 years). Throughout the study, researchers will track menstrual cycles, measure hormone levels in the blood, monitor changes in body weight and composition, and assess various health indicators related to metabolism and quality of life. Participants will need to avoid hormonal contraceptives during the study period and use alternative barrier methods for contraception.

Participants in the study will receive either the combination of RO7204239 and tirzepatide or a placebo with tirzepatide. The study will last for 48 weeks, during which participants will receive regular injections under the skin. Throughout the study, various health measurements will be taken to monitor changes in body weight, body mass index (BMI), and other health markers. These measurements will help determine the safety and effectiveness of the treatment.

The trial aims to provide valuable insights into how this new drug combination can aid in weight loss while maintaining muscle mass. By comparing the results of those receiving the active treatment with those receiving the placebo, researchers hope to better understand the potential benefits and any side effects of the treatment. The study is expected to conclude by the end of 2027.

Participants in the study will receive either Maridebart Cafraglutide or a placebo and will be monitored over a period of 72 weeks. The study will track changes in body weight, waist circumference, and other health indicators such as blood pressure and fasting glucose levels. The aim is to observe the percentage change in body weight and other health improvements over this time.

The study is designed to help understand how effective and safe Maridebart Cafraglutide is for managing weight in people without Type 2 Diabetes Mellitus. By the end of the study, researchers hope to gather valuable information on how this treatment can aid in chronic weight management and improve the quality of life for those who are overweight or have obesity.

Participants in the study will receive different doses of Wegovy, ranging from 0.25 mg to 2.4 mg, over a period of several weeks. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will monitor changes in depressive symptoms using a questionnaire called the Major Depression Inventory, which helps assess the severity of depression symptoms over time.

In addition to evaluating mood changes, the study will also look at other health factors such as body weight, waist and hip measurements, blood sugar levels, and overall quality of life. The goal is to understand how semaglutide affects both mental and physical health in individuals with depression and weight concerns. The study is expected to continue until 2027, providing valuable insights into the potential benefits of semaglutide for this group of patients.

Participants in the study will receive either Retatrutide or a placebo once a week. The study will last for a period of up to 72 weeks, during which the effects of the treatment on pain levels and body weight will be monitored. The goal is to see if Retatrutide can help reduce the average pain intensity and assist in weight loss for those who have struggled to lose weight through diet changes alone.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure the results are unbiased and reliable. The trial is expected to provide valuable insights into the potential benefits of Retatrutide for individuals dealing with obesity, overweight, and chronic low back pain.

The main purpose is to determine if using both medications together leads to greater weight loss compared to using placebo or single medications alone. The study will measure how much weight participants lose over 36 weeks of treatment. During the study, participants may also receive other medications if needed, including ondansetron, cyclizine, calcium citrate, glucose, glucagon, and various forms of calcium supplements.

Throughout the study, researchers will monitor participants’ weight changes and check for any side effects from the medications. They will also look at how many participants achieve different levels of weight loss and examine how the body responds to the medications by testing for certain proteins in the blood.

The purpose of the study is to compare the effects of different doses of PF-07976016-87 on body weight in individuals with obesity who are already using Liraglutide. Participants will be randomly assigned to receive either the study medication or a placebo, and the study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last for a period of 16 weeks, during which participants’ body weight changes will be monitored.

Throughout the study, the safety of the participants will be closely monitored, including any side effects or adverse events that may occur. The study will also assess any changes in mood or behavior using specific questionnaires. The goal is to determine the safety and effectiveness of PF-07976016-87 in helping individuals with obesity manage their weight more effectively.

The purpose of the study is to demonstrate that Orforglipron is superior to placebo in changing the Apnea-Hypopnea Index (AHI), which measures the severity of sleep apnea. Participants in the study will be randomly assigned to receive either Orforglipron or a placebo. The study will be conducted over a period of time, with participants taking the medication daily and attending regular check-ups to monitor their progress. The study will include individuals who either cannot or do not want to use Positive Airway Pressure (PAP) therapy, as well as those who are already using PAP therapy.

Throughout the study, participants will be monitored to assess changes in their Apnea-Hypopnea Index from the beginning of the study to the end, which is expected to last up to 52 weeks. The trial will help researchers understand the potential benefits of Orforglipron for people with Obstructive Sleep Apnea and weight-related issues, providing valuable insights into its safety and effectiveness.

Participants in the study will be randomly assigned to receive either Orforglipron or a placebo. The study will last for a period of time, during which participants will take the medication daily. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their body weight. The main goal is to observe the percent change in Body Mass Index (BMI) from the start of the study to the end.

This trial aims to provide valuable information on the safety and effectiveness of Orforglipron in managing weight in young people with obesity or overweight conditions. The study is designed to ensure the well-being of participants while gathering important data that could lead to new treatment options for weight management in adolescents.

The trial investigates whether using semaglutide along with a lower dose of insulin can control blood sugar levels just as effectively as using a higher dose of insulin by itself. Both medications are given through subcutaneous injection (under the skin) using pre-filled injection pens. The semaglutide is given once weekly, while insulin glargine is administered once daily.

The study lasts for 40 weeks and involves measuring changes in HbA1c (a measure of average blood sugar levels over the past 2-3 months). Participants will receive either a combination of semaglutide with reduced insulin glargine or insulin glargine alone. The study also looks at changes in body weight and how satisfied participants are with their treatment.

The purpose of the study is to understand how Metformin and lifestyle changes might affect the progression of puberty in these girls. The study will last for six months, during which participants will either receive Metformin or a placebo, and some will also participate in a lifestyle intervention. This intervention may include changes in diet and physical activity to see how these factors influence body composition and pubertal development. The main focus is on how these treatments affect bone age, which is a way to measure how quickly a child’s bones are maturing, as a marker of pubertal progression.

Throughout the study, researchers will monitor various aspects of the participants’ health, including changes in breast development, levels of sex hormones, and other metabolic markers. They will also assess body composition, fitness levels, blood pressure, heart rate, daily physical activity, and overall quality of life. The study aims to provide insights into how these interventions might help manage early puberty and its associated challenges in young girls.

The research focuses on participants with a body mass index (a measurement of body fat based on height and weight) of 27 kg/m² or higher who are 45 years or older. These individuals may or may not have type 2 diabetes, as long as their blood sugar control meets certain criteria. The study will track important health events related to both heart and kidney function over time.

During the study, participants will receive either retatrutide injections or placebo regularly, and their heart and kidney health will be monitored. The researchers will be looking specifically at events such as heart attacks, strokes, heart-related deaths, hospitalizations due to heart failure, and various indicators of kidney function decline or end-stage kidney disease.

The purpose of the study is to investigate how tirzepatide affects the composition and progression of coronary plaque, which is a buildup of substances in the arteries, and the function of small blood vessels in the heart. Participants in the study will receive either tirzepatide or a placebo once a week. The study will last for about 52 weeks, during which time the changes in the coronary plaque and the function of the heart’s small blood vessels will be monitored.

Throughout the study, participants will undergo various assessments to measure the effects of the treatment. These assessments will include imaging techniques to evaluate the coronary plaque and tests to assess the function of the heart’s small blood vessels. The goal is to understand whether tirzepatide can help improve heart health in people with coronary artery disease who are also dealing with issues related to being overweight or obese.

Participants in the study will take the medication in the form of a capsule once a day. The study will compare the weight loss results of those taking LY3502970 with those taking a placebo. The trial aims to show that LY3502970 can lead to a greater reduction in body weight compared to the placebo. The study will monitor participants over a period to assess the safety and effectiveness of the treatment.

The study is designed for individuals who have tried to lose weight through diet without success. It includes those who are overweight and have conditions such as high blood pressure, high cholesterol, sleep apnea, or heart disease. The trial will help researchers understand if LY3502970 can be a beneficial treatment option for managing weight in people with these conditions.

The purpose of the study is to evaluate the safety and tolerability of AZD9550 when given in different doses over a period of time. Participants will receive either the treatment or a placebo, and the study will monitor how the body processes the drug and its effects on the participants’ health. The study will be conducted in several parts, with each part focusing on different aspects of the treatment, such as its safety and how well it is tolerated by the body.

Throughout the study, participants will undergo regular health checks, including blood tests and other assessments, to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into the potential benefits and risks of AZD9550 for managing weight and related health conditions. Participants will be closely monitored by healthcare professionals to ensure their well-being during the trial.

Participants in the study will receive Retatrutide as a solution for injection, which means it will be given as a shot under the skin. The study will compare the effects of Retatrutide to a placebo, which is an inactive substance. The trial will be conducted in a way that neither the participants nor the researchers know who is receiving the actual treatment or the placebo, ensuring unbiased results. The study will last for a certain period, during which participants will receive the treatment once a week.

The main goal of the study is to determine if Retatrutide is more effective than the placebo in reducing knee pain and helping with weight loss. Participants will be monitored for changes in their knee pain using a specific scale and for any changes in their body weight. This study aims to provide valuable information on the potential benefits of Retatrutide for people dealing with both obesity and knee osteoarthritis.

Participants in the study will take the medication in capsule form once a day. The study will compare the weight changes in participants taking Orforglipron to those taking a placebo over a period of time. The main goal is to observe the average percentage change in body weight from the start of the study to the end, which is expected to last until 2025.

This study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The study aims to provide valuable information on the safety and effectiveness of Orforglipron for managing weight in individuals with Type 2 Diabetes who are overweight or have obesity.

The purpose of the study is to evaluate how well Retatrutide works in helping participants lose weight and manage their knee osteoarthritis symptoms. Participants will receive weekly injections and will be monitored throughout the study to assess changes in their body weight and knee pain. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants in the study will be those who have struggled with weight loss through diet alone and, for those with knee osteoarthritis, have experienced knee pain for more than 12 weeks. The study aims to provide valuable information on the potential benefits of Retatrutide for managing obesity, overweight, and knee osteoarthritis, contributing to better treatment options in the future.

Participants in the study will receive either the treatment Retatrutide or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will receive injections of the treatment or placebo. The main goal is to observe any changes in kidney function, specifically looking at a measure called the glomerular filtration rate (GFR), which indicates how well the kidneys are filtering blood. To measure this, a substance called Iohexol will be used, which helps in assessing kidney function.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, ensuring unbiased results. The trial will help determine if Retatrutide can improve kidney function in individuals with CKD, with or without Type 2 Diabetes, who are also dealing with being overweight or obesity.